Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Precancerous Conditions 4Neoplasms 2Adenomatous Polyposis Coli 2Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pain 1Leukoplakia, Oral 1Inflammation 1Hypertension 1Desmoid Tumors 1Coproporphyria 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Celecoxib 4Sulindac 2Erlotinib Hydrochloride 2Eflornithine 2Curcumin 2Surveys and Questionnaires 1Suppositories 1Sirolimus 1Sigmoidoscopy 1Gastroscopy 1Endoscopy 1Eicosapentaenoic Acid 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Adenomatous Polyposis Coli × Sulindac × Clear all
NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT01187901 2016-06-17

FAPEST

University of Utah

Phase 2 Completed
92 enrolled 11 charts
Gastrointestinal

Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡